Return to homepagePandemic Pact

Vigi-Drugs COVID-19: Early identification of the risk associated with drugs used in the context of COVID-19: analysis of global pharmacovigilance data.

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    ANR

  • Principal Investigator

    François Montastruc

  • Research Location

    France

  • Lead Research Institution

    Direction de la Recherche DRI - Centre Hospitalier Universitaire Toulouse

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Adverse events associated with therapeutic administration

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The Vigi-Drugs COVID-19 project, coordinated by François Montastruc (Direction de la Recherche DRI - Center Hospitalier Universitaire Toulouse), proposes to examine and characterize the main adverse effects of the drugs used and / or approved in the treatment of patients with of COVID-19. He will perform a weekly analysis of the WHO global pharmacovigilance database, VigiBase®, which contains more than 22 million adverse drug reactions, originating from 136 countries and covering over 90% of the world's population. He will select and evaluate the most frequent and clinically and pharmacologically relevant side effects.